FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
Dateline City:
KENILWORTH, N.J.
Patients with EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression on FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA® (pembrolizumab) monotherapy, the company’s
anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg
every three weeks, for the treatment of patients with metastatic
non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as
determined by an FDA-approved test and who have disease progression on
or after platinum-containing chemotherapy.
Language:
English
Contact:
MerckMedia Contacts:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news